# Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis

Study · id `cardio:ct-nct03256838` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03256838](<https://clinicaltrials.gov/study/NCT03256838>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03256838

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

## Technical summary

Registry record NCT03256838. Allocation not applicable; no masking; primary purpose other. Start 2017-04-12 (actual); primary completion 2018-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 202 participants (enrolled count; ClinicalTrials.gov record NCT03256838, source copy `cardio:ctgov-nct03256838-2020-01-13`, retrieved 2026-10-26)
- Started: 2017-04-12 (actual) (ClinicalTrials.gov record NCT03256838, source copy `cardio:ctgov-nct03256838-2020-01-13`, retrieved 2026-10-26)
- Primary completion: 2018-12-31 (actual) (ClinicalTrials.gov record NCT03256838, source copy `cardio:ctgov-nct03256838-2020-01-13`, retrieved 2026-10-26)
- Completion: 2019-05-31 (actual) (ClinicalTrials.gov record NCT03256838, source copy `cardio:ctgov-nct03256838-2020-01-13`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT03256838, source copy `cardio:ctgov-nct03256838-2020-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03256838-2020-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
- Condition: Kidney Failure, Chronic
- Condition: End-stage Renal Disease
- Condition: Phosphorus Metabolism Disorders
- Condition: Hyperphosphatemia
- Intervention (Drug): Ferric Citrate
- Lead sponsor: Panion & BF Biotech Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Panion & BF Biotech Inc. (`cardio:org-panion-bf-biotech-inc`)

## Provenance

Content hash: 261286e94a2e16901df85e4676008bfc8f12dadb1aa1faba683d4319a63201da
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
